Research programme: gastrointestinal disorders therapy - Williamsburg Holdings

Drug Profile

Research programme: gastrointestinal disorders therapy - Williamsburg Holdings

Alternative Names: AGI-025; Levosulpiride prodrug

Latest Information Update: 29 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Williamsburg Holdings
  • Developer AGI Therapeutics
  • Class
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 29 Jul 2011 Research programme: gastrointestinal disorders therapy is no longer licensed to AGI Therapeutics
  • 30 Aug 2007 Preclinical trials in Gastrointestinal disorders in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top